HIV vaccine strategies

Vaccine

Volumn 20, Issue 15, 2002, Pages 1945-1947

  Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV; Immunity; Vaccine

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; LIPOSOME; POL PROTEIN; PROTEIN GAG POL; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANTIBODY RESPONSE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; EXPRESSION VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AIDS VACCINES; ANIMALS; DRUG DESIGN; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; GENETIC VECTORS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MICE; MODELS, ANIMAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 0037029939     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00074-9     Document Type: Article

References (32)

1. Cytotoxic T-cell response to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
2. Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
3. Major transplantation antigens, viruses, and specificity of surveillance T cells
4. Core structure of gp41 from the HIV envelope glycoprotein
5. Atomic structure of the ectodomain from HIV-1 gp41 [see comments]
6. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression
7. Complete mutagenesis of the HIV-1 protease
8. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into virus like particles
9. Heterologous protection against influenza by injection of DNA encoding a viral protein
10. + cell-, interferon gamma-, and nitric oxide-dependent immunity
11. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
12. DNA vaccines against malaria: Immunogenicity and protection in a rodent model
13. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines
14. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
15. Vaccination against tuberculosis by injection
16. Immunization for Ebola virus infection
17. DNA immunization protects nonhuman primates against rabies virus
18. Canarypox virus-based vaccines: Prime-boost strategies to induce cell- mediated and humoral immunity against HIV
19. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates
20. Poxvirus-based vectors as vaccine candidates
21. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
22. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
23. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
24. AAV vectors: Is clinical success on the horizon?
25. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus
26. Evaluation of recombinant alphaviruses as vectors in gene therapy
27. Sindbis virus vectors for expression in animal cells
28. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
29. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
30. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo